Biosplice Executives to Discuss Knee Drug on November 1

Company leaders will appear on television to discuss a new treatment for knee osteoarthritis currently under international review.

Updated on Oct. 29, 2026 in Arthritis

Biosplice Executives to Discuss Knee Drug on November 1

Live Poll

Do you believe everyday patients should be able to formally influence the medical drug approval process?

Biosplice executives Erich Horsley and Yusuf Yazici are set to appear on the FOX Business Network program Health Uncensored with Dr. Drew on November 1, 2026. The discussion will feature their work on lorecivivint, a small-molecule kinase inhibitor designed to treat knee osteoarthritis.

Why it matters

The appearance highlights progress for a potential new treatment as the drug moves through rigorous regulatory processes in the United Kingdom and the European Union. This therapy could offer a novel approach for millions of adults suffering from the condition.

Lorecivivint is currently under review by regulators following the validation of applications in the United Kingdom on August 28, 2026, and the European Union on September 30, 2026. The drug is administered via 1-2 injections into the knee joint annually.

The players

Erich Horsley

He is an executive at Biosplice who represents the company during public engagements regarding therapeutic developments.

Yusuf Yazici

He serves as an executive at Biosplice and provides leadership in the firm's ongoing clinical and regulatory efforts.

Biosplice

Headquartered in San Diego, this biotechnology firm specializes in the development of small-molecule medicines for degenerative diseases.

The details

Lorecivivint functions by selectively inhibiting the DYRK1A and CLK2 kinases, a mechanism Biosplice has refined over more than a decade of research since identifying the compound in 2011. The treatment aims to provide an alternative for the 25 million U.S. adults currently living with knee osteoarthritis.

Biosplice identified the novel compound in 2011.
The MHRA validated the lorecivivint application on August 28, 2026.
The EMA validated the lorecivivint marketing authorization application on September 30, 2026.
Biosplice executives appear on the television segment on November 1, 2026.

Health Landscape

The development of CLK/DYRK kinase inhibitors follows a pattern set by early-stage novel kinase inhibition research, which aims to provide targeted treatments for complex degenerative diseases. This news marks a significant step forward in bringing long-researched laboratory findings into clinical application for patients.

Patients may gain access to a new non-surgical treatment option should the ongoing regulatory reviews result in approval. The drug offers a distinct administration schedule of 1-2 injections per year, which could shift daily management routines for those with chronic knee pain.

The takeaway

Advancements in targeted kinase inhibition continue to reshape how medical professionals approach the management of chronic joint degradation. Patients should consult with their physicians about current treatment limitations while awaiting further regulatory updates.